1 hr. ago
Our ***** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management reported treating 12 patients since launch, including 5 in Q2 2026, though revenue was recognized for only 4 treatments due to manufacturing variability.
The company achieved its goal of activating 7 qualified treatment centers (QTCs) by year-end, including high-volume sites like Cincinnati Children's and CHOP.
Operational complexity is driven by ZEVASKYN's 84-hour shelf life, requiring precise real-time coordination between dermatologists, surgeons, and anesthesiologists.
Patient health volatility led to two last-minute biopsy cancellations in Q2, which could not be backfilled due to the extensive pre-scheduling required for surgical slots.
#including #qtcs #chop #operational
Management reported treating 12 patients since launch, including 5 in Q2 2026, though revenue was recognized for only 4 treatments due to manufacturing variability.
The company achieved its goal of activating 7 qualified treatment centers (QTCs) by year-end, including high-volume sites like Cincinnati Children's and CHOP.
Operational complexity is driven by ZEVASKYN's 84-hour shelf life, requiring precise real-time coordination between dermatologists, surgeons, and anesthesiologists.
Patient health volatility led to two last-minute biopsy cancellations in Q2, which could not be backfilled due to the extensive pre-scheduling required for surgical slots.
#including #qtcs #chop #operational
